Principal Scientist, Cell Biology

See more jobs from Flagship Pioneering

over 2 years old

This job is no longer active

Company Summary:

FL87, Inc. is a privately held, early-stage biotechnology company developing a novel approach to gene therapy that can address currently untreatable diseases.

FL87 was founded by Flagship Pioneering, an innovation enterprise that conceives, creates, resources, and grows first-in-category life sciences companies. Flagship Pioneering has created over 100 groundbreaking companies over the past twenty years, all of which are pioneering novel and proprietary biological, industrial, and engineering approaches to solve major needs in human health and sustainability. These companies include Seres Therapeutics (NASDAQ:MCRB), Moderna (MRNA), Syros Pharmaceuticals (SYRS), Rubius Therapeutics (RUBY), Axcella Health, Evelo Biosciences (EVLO), and Indigo Agriculture.

Position Summary:

The Principal Scientist will be responsible for the execution and development of various molecular assay protocols. This individual will join a dynamic, rapidly growing, and highly collaborative team that combines significant biologic drug discovery experience with pioneering discoveries driving a novel biological platform.

Key Responsibilities:

  • The successful candidate will work both independently and as part of a collaborative team to design, plan and execute experiments that support research activities, project goals, and platform develop.
  • Oversight of a team of 2+ scientists and research associates to ensure rapid and high-quality execution of molecular assays on candidates
  • Screen candidate medicines using quantitative molecular assays
  • The team will be responsible for:
    • Mammalian cell culture and transfection and/or transduction
    • Flow cytometry analysis of cell populations
    • Quantitative PCR and digital droplet PCR
    • Next generation sequencing
    • Fluorescent and bioluminescent microscopy
    • Western blotting or ELISA
  • Managing external relationships with contract research organizations
  • Design, execution, and troubleshooting of experiments as well as data analysis
  • Maintaining lab notebooks and reporting data and analysis results to the scientific team

Basic Qualifications:

  • Ph.D. in Molecular Biology, Biochemistry, Genetics, Immunology or related field with 5+ years of industry experience is required.
  • Prior experience with quantitative assessment of on-target/off-target and cell penetrance for gene editing, gene therapy, or RNA interference.
  • Proven hands-on experience with cell-based and molecular biology assays with a variety of readout technologies, such as, but not limited to: flow cytometry, quantitative PCR, next generation sequencing.
  • Experience with primary cell and animal models
  • Experience independently generating precise, reliable data and skillfully analyzing the data.
  • Excellent communication and presentation skills, capable of conveying technical information in a clear and thorough manner.
  • A strong self-starter, independent thinker, with a strong attention to detail.
  • Eager to work with highly-skilled and dynamic teams in a fast-paced, entrepreneurial and technical setting.
  • Demonstrated industry experience or academic achievement, as evidenced by publications in high impact journals or drug development is required
  • Previous experience managing multiple bench researchers

Preferred Qualifications:

  • Post-doctoral experience
  • Strong experience with mammalian cell culture techniques.
  • Experience with delivery of gene editing, gene therapy, or RNA interference technologies in vivo or to ex vivo primary cells

 

More About Flagship Pioneering

We are creative optimists and we would love for you to consider joining our team!  See all our open opportunities across Flagship Pioneering’s Ecosystem!

Flagship Pioneering conceives, creates, resources, and develops first-in-category life sciences companies to transform human health and sustainability. Since its launch in 2000, the firm has applied a unique hypothesis-driven innovation process to originate and foster more than 100 scientific ventures, resulting in over $34 billion in aggregate value. To date, Flagship is backed by more than $4.4 billion of aggregate capital commitments, of which over $1.9 billion has been deployed toward the founding and growth of its pioneering companies alongside more than $10 billion of follow-on investments from other institutions. The current Flagship ecosystem comprises 41 transformative companies, including:  Axcella Health (NASDAQ: AXLA), Denali Therapeutics (NASDAQ: DNLI), Evelo Biosciences (NASDAQ: EVLO),  Foghorn Therapeutics, Indigo Ag, Kaleido Biosciences (NASDAQ: KLDO), Moderna (NASDAQ: MRNA), Rubius Therapeutics (NASDAQ: RUBY), Sana Biotechnology, Seres Therapeutics (NASDAQ: MCRB), and Syros Pharmaceuticals (NASDAQ: SYRS).

We believe pioneering is best done by teams, and that it is a process that can be taught, learned, and replicated.  Learn more about our Company Creation Model.

Can Breakthrough Innovations Be Made Systematically? A Conversation With Noubar Afeyan, Flagship Pioneering’s CEO.

 

Flagship Pioneering and our ecosystem companies are committed to equal employment opportunity regardless of race, color, ancestry, religion, sex, national origin, sexual orientation, age, citizenship, marital status, disability, gender identity or Veteran status.

 

Recruitment & Staffing Agencies:  Flagship Pioneering and its affiliated Flagship Lab companies (collectively, “FSP”) do not accept unsolicited resumes from any source other than candidates.  The submission of unsolicited resumes by recruitment or staffing agencies to FSP or its employees is strictly prohibited unless contacted directly by Flagship Pioneering’s internal Talent Acquisition team.   Any resume submitted by an agency in the absence of a signed agreement will automatically become the property of FSP, and FSP will not owe any referral or other fees with respect thereto.